Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study

被引：0
|
作者：
Miles, D.
Baselga, J.
Amadori, D.
Sunpaweravong, P.
Semiglazov, V.
Knott, A.
Clark, E.
Ross, G.
Swain, S. M.
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy
[5] Prince Songkla Univ, Songklanagarind Hosp, Hat Yai, Thailand
[6] NN Petrov Res Inst Oncol, St Petersburg, Russia
[7] Roche Prod Ltd, Welwyn Garden City, England
[8] MedStar Washington Hosp Ctr, Washington, DC USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P5-18-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-18-01
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumab
    Gil, Eva Maria Ciruelos
    Brufsky, Adam
    Im, Young-Hyuck
    Kim, Sung-Bae
    Clark, Emma
    Knott, Adam
    Ross, Graham
    Miles, David
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report
    Yamashita, Yuji
    Tanaka, Yuko
    Kono, Seishi
    Nishimura, Meiko
    Mukohara, Toru
    Morinaga, Yukiko
    Hara, Shigeo
    Takao, Shintaro
    BREAST CARE, 2017, 12 (01) : 45 - 47
  • [23] Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
    Yamashita-Kashima, Yoriko
    Shu, Sei
    Yorozu, Keigo
    Moriya, Yoichiro
    Harada, Naoki
    ONCOLOGY LETTERS, 2017, 14 (04) : 4197 - 4205
  • [24] Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
    Yu, Anthony F.
    Manrique, Carlos
    Pun, Shawn
    Liu, Jennifer E.
    Mara, Elton
    Fleisher, Amartin
    Patil, Sujata
    Jones, Lee W.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2016, 21 (04): : 418 - 424
  • [25] Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
    Lee, Yong-Pyo
    Lee, Min-Sang
    Kim, HongSik
    Kim, Ji-Yeon
    Ahn, Jin Seok
    Im, Young-Hyuck
    Park, Yeon Hee
    CANCER RESEARCH AND TREATMENT, 2022, 54 (04): : 1130 - 1137
  • [26] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Emi Noguchi
    Kenji Tamura
    Masaya Hattori
    Jun Horiguchi
    Nobuaki Sato
    Kazumitsu Kanatani
    Kiyoshi Matsunaga
    Hiroji Iwata
    Yasuhiro Fujiwara
    Breast Cancer, 2019, 26 : 39 - 46
  • [27] Efficacy and safety of neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab in patients with HER2-positive early breast cancer - A retrospective study
    Koudsi, L.
    Hockaday, C.
    Levitt, N.
    Tuthill, M.
    Roux, R.
    Lord, S.
    Chiramel, J.
    CLINICAL ONCOLOGY, 2025, 38
  • [28] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Noguchi, Emi
    Tamura, Kenji
    Hattori, Masaya
    Horiguchi, Jun
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Matsunaga, Kiyoshi
    Iwata, Hiroji
    Fujiwara, Yasuhiro
    BREAST CANCER, 2019, 26 (01) : 39 - 46
  • [29] Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
    Wang, B.
    You, S.
    Xie, Y.
    Xu, F.
    Sang, D.
    Luo, T.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S362
  • [30] Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer
    Irelli, Azzurra
    Ceriello, Laura
    Patruno, Leonardo Valerio
    Tessitore, Alessandra
    Alesse, Edoardo
    Cannita, Katia
    Fabiani, Donatello
    BIOMEDICINES, 2024, 12 (01)
12345